Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma

Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma

Inflammatory IL-6/STAT3 signaling is constitutively activated in diverse cancers and is associated with malignant cell proliferation, invasion and escape of antitumor immunosurveillance. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is commonly used to treat insulin-resistant diabetes. In t...

Full description

Bibliographic Details
Main Authors: Xian Lu, Chun Xu, Jie Dong, Shuguang Zuo, Hailin Zhang, Chunping Jiang, Junhua Wu, Jiwu Wei
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320303648

Similar Items

Similar Items